Alpha-Methylacyl-CoA Racemase (AMACR) Antibody

Background

Alpha-Methylacyl-CoA Racemase (AMACR) is a mitochondrial and peroxisomal enzyme that catalyzes the racemization of alpha-methyl-branched fatty acid derivatives and bile acid intermediates, enabling their further metabolism via beta-oxidation. AMACR is critical in lipid metabolism, particularly in the breakdown of dietary branched-chain fatty acids and the processing of bile acids derived from cholesterol. It is highly expressed in tissues with active fatty acid metabolism, such as the liver and kidneys. Dysregulation or mutations in the AMACR gene are associated with metabolic disorders, including adult-onset sensory neuropathy and bile acid metabolism defects. Additionally, AMACR is a well-established biomarker for prostate cancer and other malignancies, as its overexpression is linked to cancer cell metabolism and tumor progression. Targeting AMACR enzymatic activity is being explored as a therapeutic strategy in cancer and metabolic disorders.